iHuman Inc. (IH)

NYQ – Real vaqt narxi. Valyuta: USD

1.40

+0.02 (1.45%)

Yopilishda: Jun 26, 2026, 1:25 PM EDT

1.40

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 5:05 PM EDT

16.06.2026

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation For U.S. media and investors only DUBLIN, June 16, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic impacts of reduced sodium exposure in patients living with these debilitating conditions.

31.05.2026

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

BEIJING, May 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced that it has entered into certain asset transfer agreements to acquire the businesses and assets related to two products, All Knowledge (全知识) and Perfect Lingo (万词王) (the "Acquisitions"), for an aggregate consideration of RMB94.0 million, subject to potential two-way price adjustments and contingent earn-out payments. All Knowledge is an app that focuses on humanities and AI literacy, providing users with AI-powered interactive access to knowledge across history, culture, literature, philosophy, art, and other humanities fields.

24.04.2026

iHuman Inc. Files 2025 Annual Report on Form 20-F

BEIJING, April 24, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced that it filed its annual report on Form 20-F for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission on April 24, 2026. The annual report on Form 20-F is available on the Company's investor relations website at https://ir.ihuman.com/.

31.03.2026

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

BEIJING, March 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Highlights Revenues were RMB190.7 million (US$27.3 million), compared with RMB232.7 million in the same period last year.

29.12.2025

iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

BEIJING , Dec. 29, 2025 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Revenues were RMB205.8 million (US$28.9 million), compared with RMB239.4 million in the same period last year.

25.11.2025

iHuman: Undervalued With Geographical Expansion Upside

iHuman (IH) offers educational apps and devices, trading at a deep discount to global peers and below its cash value, signaling undervaluation. IH is expanding internationally, notably in the US through a partnership with Cricket Media, diversifying away from China policy risks. Despite revenue declines, IH achieved strong net income growth in 2Q25 due to significant cost reductions, and maintains a highly liquid balance sheet.

24.11.2025

iHuman to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Beijing, China--(Newsfile Corp. - November 24, 2025) - iHuman Inc. (NYSE: IH), a leading provider of tech-powered, intellectual development products in China, today announced that its Investor Relations Director, Justin Zhang, will present at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL., on Wednesday, December 3rd at 12:00 PM Eastern Standard Time.

Videolar

No Data

There is no data to display

Press-relizlar

16.06.2026

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

31.05.2026

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

24.04.2026

iHuman Inc. Files 2025 Annual Report on Form 20-F

31.03.2026

iHuman Inc. (IH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

iHuman Inc. (IH)

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

iHuman: Undervalued With Geographical Expansion Upside

iHuman to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Videolar

No Data

Press-relizlar

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

iHuman: Undervalued With Geographical Expansion Upside

iHuman to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Videolar

No Data

Press-relizlar

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

Search stocks

iHuman Inc. (IH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

iHuman Inc. (IH)

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

iHuman: Undervalued With Geographical Expansion Upside

iHuman to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Videolar

No Data

Press-relizlar

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

iHuman: Undervalued With Geographical Expansion Upside

iHuman to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Videolar

No Data

Press-relizlar

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

iHuman Inc. Files 2025 Annual Report on Form 20-F

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results